Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Cervarix Clears Landmark FDA Vaccine Committee with Okay for Novel Adjuvant

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline's two-year delay to do more safety work on the vaccine and specifically on the AS04 adjuvant gets the sponsor past one major milestone with a strong vote on safety for use in girls and young women.

You may also be interested in...



Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav

FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.

FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population

The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.

FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population

The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.

Topics

UsernamePublicRestriction

Register

PS070078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel